Bendeka
Total Payments
$95,376
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $95,376 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $95,376 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase I/II study of Gemcitabine and Bendamustine in patients with relapsed or refractory Hodgkin's Lymphona | Teva Pharmaceuticals USA, Inc. | $79,856 | 0 |
| Phase II study for the evaluation of Bendamustin, Bortezomib and Dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy | Teva Pharmaceuticals USA, Inc. | $15,520 | 0 |
Top Doctors Receiving Payments for Bendeka
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $95,376 | 3 |
Ad
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $95,376
Product Information
- Type Drug
- Total Payments $95,376
- Total Doctors 0
- Transactions 3
About Bendeka
Bendeka is a drug associated with $95,376 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2020 to 2020. In 2020, $95,376 was paid across 3 transactions to 0 doctors.
The most common payment nature for Bendeka is "Unspecified" ($95,376, 100.0% of total).
Bendeka is associated with 2 research studies, including "Phase I/II study of Gemcitabine and Bendamustine in patients with relapsed or refractory Hodgkin's Lymphona" ($79,856).